# First in Human Study of AZD9592 in Solid Tumors

Source: https://onco.cc/trials/nct05647122/  
OnCo record `nct05647122` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of Tilatamig samrotecan, Osimertinib, Fluorouracil and Leucovorin in Head and neck squamous cell carcinoma, run by AstraZeneca, active and no longer recruiting.

## Summary

First in Human Study of AZD9592 in Solid Tumors is a phase 1 interventional study registered as NCT05647122 by AstraZeneca, with 167 participants planned, started 2022-12-21 and due to reach its primary completion in 2028-08-03. Interventions recorded: AZD9592, Osimertinib, 5-Fluorouracil (5-FU), Leucovorin, Bevacizumab. Conditions recorded: Advanced Solid Tumours, Carcinoma Non-small Cell Lung, Head and Neck Neoplasms, Colorectal Neoplasms.

Linked to the drug Tilatamig samrotecan because the registry names it among its interventions and Head and neck squamous cell carcinoma among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05647122
- Phase: 1
- Setting: A Phase I, Multicenter, Open-label, First-in-Human, Dose Escalation and Expansion Study of AZD9592 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumors
- Sponsor: AstraZeneca
- Enrolled: 167

## Sources

- ClinicalTrials.gov NCT05647122: https://clinicaltrials.gov/study/NCT05647122

## Connected records

- cancers: [Head and neck squamous cell carcinoma](https://onco.cc/cancers/head-and-neck/)
- drugs: [Fluorouracil (5-FU)](https://onco.cc/drugs/fluorouracil/), [Leucovorin (folinic acid)](https://onco.cc/drugs/leucovorin/), [Osimertinib](https://onco.cc/drugs/osimertinib/), [Tilatamig samrotecan](https://onco.cc/drugs/tilatamig-samrotecan/)

---
JSON: https://onco.cc/api/v1/entities/nct05647122.json